Treatment for prostate cancer (PCa) has evolved significantly over the last decade.
PCa is the most prevalent non-skin cancer and the second leading cause of cancer death in men, and it has an increased incidence and prevalence in older men. As a result, physicians and patients are faced with the challenge of identifying optimal treatment strategies for localized, biochemical recurrent, and advanced PCa in the older population. When older patients are appropriately selected, treatment for PCa results in survival benefits and toxicity profiles similar to those experienced in younger patients. However, underlying health status and age-related changes can have an impact on tolerance of hormonal therapy and chemotherapy in men with advanced disease. Therefore, the heterogeneity of the elderly population necessitates a multidimensional assessment to maximize the benefit of medical and/or surgical options. Providing clinicians with the requisite health status data on which to base treatment decisions would help ensure that older patients with PCa receive optimal therapy if it will benefit them and/or active surveillance or best supportive care if it will not. We provide a review of the existing evidence to date on the management of PCa in the older population.
Fung C, Dale W, Mohile SG. Are you the author?
2Chunkit Fung and Supriya Gupta Mohile, University of Rochester, Rochester, NY; and William Dale, University of Chicago, Chicago, IL.
Reference: J Clin Oncol. 2014 Jul 28. pii: JCO.2014.55.1531.